Citius Oncology Reports Promising LYMPHIR Cancer Data
CRANFORD, N.J., June 1, 2026 Citius Oncology has announced encouraging Phase 1 clinical findings evaluating LYMPHIR® (denileukin diftitox-cxdl) in...
progression-free survival
Advertisement
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
Merck Sac-TMT Trial Shows Survival Benefit in Cancer
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
Advertisements
Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
Pfizer ELREXFIO Phase 3 Trial Improves Survival Outcomes
New York, United States | April 29, 2026 Pfizer Inc. has reported positive Phase 3 clinical trial results for...
Phase III Study Shows Giredestrant Boosts Breast Cancer Survival
Basel, Switzerland — September 22, 2025 — Positive phase III trial results from the evERA study reveal that the...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
